- Raised $8M funding round, May 2017
- Raised $2.3M funding round, Dec 2015
- Raised funding round, Nov 2019
About
Protekt Therapeutics is a biopharmaceutical company aiming to identify and develop a potent and selective oral PKR inhibitor (PKRi) to treat cognitive disorders such as Alzheimers disease and mild cognitive impairment. PKR is a stress and proapoptotic kinase that phosphorylates eIF2, a key protein in the translation machinery, and results in inhibition of protein synthesis and impaired memory consolidation.
PKR is also activated during apoptosis, autophagy, neuroinflammation, and A peptide toxicity, which are prominent features of Alzheimer's Disease (AD). Therefore, PKR inhibition offers a novel and promising disease-modifying mechanism for modulating multiple key processes in AD and other neurodegenerative diseases.
ProteKt Therapeutics was established in the FutuRx Incubator in December 2015 based on technology from Prof. Kobi Rosenblum's lab (Haifa University) and is now fully owned by Bukwang Pharmaceutical.
Funding history · 4 rounds · $13.8M total
Q&A
- What is Protekt Therapeutics' primary focus?
- Protekt Therapeutics is a biopharmaceutical company focused on identifying and developing a potent and selective oral PKR inhibitor (PKRi) to treat cognitive disorders such as Alzheimer's disease and mild cognitive impairment.
- When was Protekt Therapeutics founded?
- Protekt Therapeutics was founded in December 2014.
- How many employees does Protekt Therapeutics have?
- Protekt Therapeutics has 1-10 employees.
- Who are some of the investors in Protekt Therapeutics' funding rounds?
- Investors in Protekt Therapeutics' funding rounds include OrbiMed and Johnson & Johnson Innovation.
- What is the total amount of funding raised by Protekt Therapeutics?
- Protekt Therapeutics has raised a total of $13,850,000 USD.
- What is the current ownership status of Protekt Therapeutics?
- Protekt Therapeutics is fully owned by Bukwang Pharmaceutical.
- When did Protekt Therapeutics receive its last known funding round?
- Protekt Therapeutics received its last known funding round in November 2019.
- What is the scientific basis for Protekt Therapeutics' approach?
- Protekt Therapeutics' approach is based on technology from Prof. Kobi Rosenblum's lab at Haifa University, focusing on PKR inhibition to modulate processes in Alzheimer's Disease and other neurodegenerative diseases.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | protektx.com/ |
|---|---|
| facebook.com/Protektx |
Identifiers & details
| Former names | MemoFit |
|---|---|
| Founded | 2014-12 |
| Employees (exact) | 2 |
Radar intelligence
Patents
| EPO | 1 |
|---|
Web history (Wayback)
| Domain | protektx.com |
|---|